avalglucosidase alfa Special Drug Use Investigation for patients with pompe disease

avalglucosidase alfa Special Drug Use Investigation for patients with pompe disease - avalglucosidase alfa Special Drug Use Investigation for patients with pompe disease

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000047301

Enrollment

Registered

2022-03-28

Start date

2022-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pompe disease

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with Pompe disease who are newly treated with Nexviazyme

Exclusion criteria

Exclusion criteria: -Individuals participating in or enrolling in other clinical trials involving therapeutic interventions of Nexviazyme -Those with off-label use of Nexviazyme

Design outcomes

Primary

Measure	Time frame
Safety (Adverse Drug Reaction)	—

Secondary

Measure	Time frame
Efficacy	—

Countries

Japan

Contacts

Public ContactPublic contact for Drug use surveillance Public contact for Drug use surveillance

Medical Affairs Post-authorization regulatory studies

Sanofi_Medical@sanofi.com03-6301-3867

Outcome results